SPY S&P 500 etf Oversold on the RSI ! 2025 Price Target ! The SPDR S&P 500 ETF Trust (SPY) is flashing a major buy signal, with its Relative Strength Index (RSI) currently sitting at 28.33 — firmly in oversold territory. Historically, every time SPY has entered oversold levels on the RSI, institutional buyers have stepped in aggressively, driving sharp rebounds in the following weeks and months.
The last time SPY dipped below the 30 RSI threshold was during market pullbacks in 2022 and 2023 — both of which were followed by significant rallies as institutions capitalized on discounted valuations. The current setup is no different. With earnings growth stabilizing, inflation cooling, and the Federal Reserve signaling a potential shift toward rate cuts in the second half of the year, the backdrop for a recovery is aligning perfectly.
Technically, SPY is also approaching key support levels that have held strong in past market corrections. The combination of an oversold RSI and strong institutional appetite at these levels creates a compelling case for a bounce.
My price target for SPY by year-end is $640, representing over 15% upside from current levels. With sentiment stretched to the downside and technical indicators flashing green, SPY looks primed for a sharp and sustained rebound. Now could be the perfect time to position for the next leg higher.
Signalsgroup
TDOC Teladoc Health Options Ahead of EarningsAnalyzing the options chain and the chart patterns of TDOC Teladoc prior to the earnings report this week,
I would consider purchasing the 20usd strike price Calls with
an expiration date of 2026-1-16,
for a premium of approximately $1.04.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
SRPT Sarepta Therapeutics Options Ahead of EarningsAnalyzing the options chain and the chart patterns of SRPT Sarepta Therapeuticsprior to the earnings report this week,
I would consider purchasing the 120usd strike price Calls with
an expiration date of 2025-8-15,
for a premium of approximately $9.30.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
BMBL Bumble Options Ahead of EarningsAnalyzing the options chain and the chart patterns of BMBL Bumble prior to the earnings report this week,
I would consider purchasing the 8usd strike price Calls with
an expiration date of 2025-4-17,
for a premium of approximately $1.52.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
PANW Palo Alto Networks Options Ahead of EarningsSnalyzing the options chain and the chart patterns of PANW Palo Alto Networks prior to the earnings report this week,
I would consider purchasing the 195usd strike price Calls with
an expiration date of 2025-2-21,
for a premium of approximately $9.90.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
AMAT Applied Materials Options Ahead of EarningsAnalyzing the options chain and the chart patterns of AMAT Applied Materials prior to the earnings report this week,
I would consider purchasing the 180usd strike price Calls with
an expiration date of 2025-2-21,
for a premium of approximately $6.75.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
ABBV AbbVie Options Ahead of EarningsIf you haven`t bought ABBV before the previous earnings:
Now analyzing the options chain and the chart patterns of ABBV AbbVie prior to the earnings report this week,
I would consider purchasing the 175usd strike price Calls with
an expiration date of 2025-2-21,
for a premium of approximately $6.20.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
CMCSA Comcast Corporation Options Ahead of EarningsAfter CMCSA reached the previous price target:
Now analyzing the options chain and the chart patterns of CMCSA Comcast Corporation prior to the earnings report this week,
I would consider purchasing the 40usd strike price Calls with
an expiration date of 2025-6-20,
for a premium of approximately $1.86.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
DFS Discover Financial Services Options Ahead of EarningsIf you haven`t bought DFS before the previous earnings:
Now analyzing the options chain and the chart patterns of DFS Discover Financial Services prior to the earnings report this week,
I would consider purchasing the 190usd strike price Calls with
an expiration date of 2025-2-21,
for a premium of approximately $6.65.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
SLB Schlumberger Limited Options Ahead of EarningsIf you haven`t sold the Double Top on SLB:
Now analyzing the options chain and the chart patterns of SLB Schlumberger prior to the earnings report this week,
I would consider purchasing the 40usd strike price Puts with
an expiration date of 2025-6-20,
for a premium of approximately $3.17.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
HELE Helen of Troy Limited Options Ahead of EarningsIf you haven`t sold HELE before the previous earnings:
Now analyzing the options chain and the chart patterns of HELE Helen of Troy Limited prior to the earnings report this week,
I would consider purchasing the 70usd strike price Calls with
an expiration date of 2025-1-17,
for a premium of approximately $1.32.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
BIDU Baidu Among My Top 10 Picks for 2025 | Price TargetIf you ahven`t bought the dip on BIDU:
My price target for BIDU in 2025 is $120, driven by the following fundamental factors:
Strong Domestic Market Growth:
Baidu continues to experience robust growth in its domestic market, particularly in its online marketplace, which reported a remarkable 24% year-over-year increase in the third quarter of 2024. This growth significantly outpaces industry averages and positions Baidu favorably against competitors. Analysts project mid-teen growth for Baidu in fiscal year 2025, driven by increased demand for its services and products within China, which remains one of the largest digital markets globally.
AI-Driven Revenue Expansion:
The company's commitment to an AI-first strategy is a major driver of its future growth. Baidu's AI Cloud business has shown resilience, with an 11% increase in revenue attributed to AI-related services. As businesses increasingly adopt AI technologies, Baidu is well-positioned to capitalize on this trend, enhancing its revenue streams and profitability. The anticipated improvements in monetization of AI search technologies further bolster this outlook.
Valuation and Financial Health:
Baidu's current valuation presents an attractive opportunity for investors. Trading at approximately 8.6 times its fiscal year 2025 earnings estimate, the stock appears undervalued compared to its peers. The company boasts a strong balance sheet with a net cash position of around $15 billion, providing a cushion for continued investments in growth initiatives without excessive debt burdens. Additionally, Baidu's price-to-earnings (P/E) ratio of about 10.8 suggests significant upside potential as market sentiment shifts positively.
Strategic Investments and Share Buybacks:
Baidu is actively investing in its ecosystem, focusing on merchant support and logistics improvements. While these investments may impact margins in the short term, they are expected to yield long-term benefits through enhanced operational efficiencies and increased market share. Furthermore, Baidu's ongoing share buyback program demonstrates management's confidence in the company's future prospects and commitment to returning value to shareholders.
MRNA Moderna Among My Top 10 Picks for 2025 | Price TargetIf you haven`t bought MRNA on the recent breakout:
My price target for MRNA in 2025 is $55, driven by the following fundamental factors:
Innovative mRNA Technology and Expanding Pipeline:
Moderna has established itself as a leader in mRNA technology, initially gaining prominence through its COVID-19 vaccine. The company is now leveraging this innovative platform to develop a diverse array of therapeutic candidates, with approximately 40 development projects in progress across various fields, including infectious diseases, oncology, and rare genetic disorders. This broad pipeline not only enhances Moderna's potential for future revenue but also positions it to capitalize on emerging healthcare needs as the demand for advanced therapies continues to rise.
Projected Revenue Growth:
Despite facing financial challenges, including recent losses, Moderna's revenue outlook remains promising. The company is forecasting sales between $2.5 billion and $3.5 billion for 2025, which analysts believe could be conservative given the anticipated rollout of new vaccines and treatments. If successful, these products could significantly boost sales and profitability, driving investor confidence and stock price appreciation 16. Market projections suggest that if Moderna successfully navigates its clinical trials and product launches, the stock could reach around $80 per share by 2025.
Strategic Partnerships and Collaborations:
Moderna's strategic collaborations with major pharmaceutical companies enhance its development capabilities and market access. These partnerships are crucial for accelerating product development and increasing the adoption of its mRNA technology across various therapeutic areas. By aligning with established players in the industry, Moderna can leverage additional resources and expertise to bring its innovations to market more effectively.
Market Sentiment and Recovery Potential:
Currently trading at lower valuations due to past performance fluctuations, Moderna's stock is positioned for recovery as investor sentiment shifts with positive developments in its pipeline. The company's five-year growth trajectory shows resilience despite recent setbacks, indicating potential for a rebound as new products come to market. Analysts remain optimistic about Moderna's long-term prospects, suggesting that as the market recognizes the value of its innovative therapies, the stock could see substantial gains.
NVDA Nvidia Among My Top 10 Picks for 2025 | Price TargetIf you haven`t bought the recent dip on NVDA:
My price target for NVDA in 2025 is $170, driven by the following fundamental factors:
Dominance in AI and Data Center Markets:
NVIDIA is a leader in the artificial intelligence (AI) and data center sectors, which are expected to experience exponential growth. The company's GPUs are critical for AI applications, and its data center revenue has surged dramatically, reaching $14.51 billion in Q3 2023—a threefold increase year-over-year. Analysts predict that NVIDIA's revenue could reach approximately $111.3 billion in 2025, driven by the relentless demand for AI technologies and the expansion of data center capabilities.
Innovative Product Pipeline:
The upcoming introduction of NVIDIA's Blackwell architecture is set to enhance its competitive edge further. This new line of chips is designed to deliver unprecedented performance levels for AI applications, solidifying NVIDIA's leadership in the sector. The anticipated demand for these advanced products is expected to bolster revenue and profitability significantly. Additionally, NVIDIA's continuous investment in research and development ensures that it remains at the forefront of technological advancements.
Strong Financial Performance and Market Sentiment:
NVIDIA has demonstrated robust financial health, with gross margins consistently above 70% and earnings per share (EPS) forecasts reflecting strong growth. The company has also engaged in substantial share repurchase programs, returning value to shareholders while signaling confidence in its future performance. Market sentiment remains overwhelmingly positive, with analysts frequently upgrading their price targets based on NVIDIA's strong fundamentals and growth trajectory.
MITK Mitek Systems Options Ahead of EarningsAnalyzing the options chain and the chart patterns of MITK Mitek Systems prior to the earnings report this week,
I would consider purchasing the 12.50usd strike price Calls with
an expiration date of 2025-4-17,
for a premium of approximately $0.48.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
FIVE Five Below Options Ahead of EarningsAnalyzing the options chain and the chart patterns of FIVE Five Below prior to the earnings report this week,
I would consider purchasing the 100usd strike price Calls with
an expiration date of 2024-12-20,
for a premium of approximately $5.00.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
ASTS AST SpaceMobile Options Ahead of EarningsIf you haven`t bought ASTS before the major breakout:
Now analyzing the options chain and the chart patterns of ASTS AST SpaceMobile prior to the earnings report this week,
I would consider purchasing the 25usd strike price Calls with
an expiration date of 2025-5-16,
for a premium of approximately $6.60.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
CLOV Clover Health Investments Options Ahead of EarningsAnalyzing the options chain and the chart patterns of CLOV Clover Health Investments prior to the earnings report this week,
I would consider purchasing the 5usd strike price Calls with
an expiration date of 2025-1-17,
for a premium of approximately $0.51.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
ETH Ethereum Potential retracement soonIf you haven`t bought the recent Double Bottom on ETH:
Now Ethereum might be facing bearish pressure following the U.S. Department of Justice's (DOJ) launch of a criminal investigation into Tether, the issuer of the widely used stablecoin USDT.
According to reports from the Wall Street Journal, this investigation is led by the U.S. attorney’s office in Manhattan and focuses on potential violations of sanctions and anti-money laundering regulations.
As Tether’s USDT is a crucial component of the cryptocurrency ecosystem, widely utilized for trading and liquidity on various platforms, any negative developments regarding its regulatory compliance could have significant ramifications for Ethereum. Tether's stability and its ability to maintain its peg to the U.S. dollar are vital for many trading pairs involving Ethereum. If the investigation reveals serious issues, it could lead to a loss of confidence in USDT, prompting traders to seek safer alternatives or even pull out of the market altogether.
The ripple effects of Tether’s troubles may extend to Ethereum and other cryptocurrencies that depend on stablecoins for liquidity. A decline in USDT’s credibility could trigger panic selling, as traders rush to liquidate their positions in Ethereum and other assets, leading to increased volatility and downward pressure on prices. This scenario could particularly impact Ethereum, given its integral role in decentralized finance (DeFi), where USDT is frequently used for collateral and trading.
The scrutiny surrounding Tether may prompt regulators to cast a wider net over the cryptocurrency market, leading to increased oversight of other stablecoins and projects operating on the Ethereum network. This heightened regulatory environment could deter new investments and innovations within the Ethereum ecosystem, hindering its growth potential.
HOOD Robinhood Markets Options Ahead of EarningsIf you haven`t bough HOOD before the major breakout:
Now analyzing the options chain and the chart patterns of HOOD Robinhood Markets prior to the earnings report this week,
I would consider purchasing the 26usd strike price Calls with
an expiration date of 2024-11-1,
for a premium of approximately $2.00.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
MS Morgan Stanley Options Ahead of EarningsAnalyzing the options chain and the chart patterns of MS Morgan Stanley prior to the earnings report this week,
I would consider purchasing the 115usd strike price Calls with
an expiration date of 2024-11-15,
for a premium of approximately $2.26.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
VZ Verizon Communications Options Ahead of EarningsAnalyzing the options chain and the chart patterns of VZ Verizon Communications prior to the earnings report this week,
I would consider purchasing the 44usd strike price Calls with
an expiration date of 2024-11-15,
for a premium of approximately $1.23.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
APLD Applied Digital Corporation Options Ahead of EarningsIf you haven`t bought the dip on APLD:
Now analyzing the options chain and the chart patterns of APLD Applied Digital Corporation prior to the earnings report this week,
I would consider purchasing the 9usd strike price Calls with
an expiration date of 2024-11-15,
for a premium of approximately $1.10.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.